

MAY 05 2009

PTO/SB/08 (2/92)

Sheet 1 of 1

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT

Attorney's Docket No.

GNE-0151-D2

Application Serial No.

10/644,875

Applicant(s)

Ying-Fei Wei, et al.

(use several sheets if necessary)

Filing Date:

August 21, 2003

Group Art Unit:

1647

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	1.	09/18/2003	WO 03/075855 A2	WIPO				
	2.	12/15/2005	WO 2005/117986 A2	WIPO				
	3.	03/30/2006	WO 2006/034488 A2	WIPO				
	4.	12/06/2007	WO 2007/140371 A2	WIPO				
	5.	11/20/2008	WO 2008/141044 A2	WIPO				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	6.	Junutula, et al., "ThioMabs: Improving Safety And Retaining Efficacy Of Antibody Drug Conjugates", AACR, Vol. 48, pages 220-221, (2007)
	7.	Lambert, et al., "Drug-Conjugates Monoclonal Antibodies For The Treatment Of Cancer", Current opinion in pharmacology, Vol. 5, No. 5, pages 543-549, (2005)
	8.	Mao, et al., "Tenb2 As A Therapeutic Antibody Drug Target For The Treatment Of Prostate Cancer", MCT, Vol. 6, No. 12, page 3356S, (2007)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).